POSTER DISCUSSION PRESENTATIONS  by unknown
Purpose/Objective(s): Tumor expression of isoform 3T is an unfavorable
prognostic factor in several tumor types, including NSCLC treated with
standard tubulin-inhibiting chemotherapy agents. IXA is a semi-synthetic
epothilone B analog with low susceptibility to multiple tumor resistance
mechanisms in several tumor models. A randomized, international phase 2
study was conducted to explore if IXA-based chemotherapy can improve
prognosis in patients (pts) with stage IIIb/IV NSCLC whose tumors are
positive for 3T (3T).
Materials/Methods: 197 pts were randomized 1:1 and stratified by expres-
sion level of 3T status (positive/negative), to receive either IXA (32 mg/m2)
and C (AUC6) (N98) or P (200 mg/m2) and C (AUC6) (N99) on Day
1 of a 21 day cycle (cyc) for up to 6 cyc. The primary endpoint compared
PFS between IXA/C vs P/C in the 3T subgroup. The study was powered
to detect a hazard ratio (HR) of 0.58 using a two-sided 0.20 log-rank test
with 90% power. 3T expression was measured in central lab on baseline
tumor tissues using a standardized IHC assay developed by Dako; positivity
was pre-defined as 50% of tumor cells classified as 2 or 3.
Results: There were 104 3T and 93 3T negative (3T-) pts. 95 pts (52
3T and 43 3T-) received IXA/C and 96 pts (49 3T and 47 3T-)
received P/C. Median PFS (mPFS) in the 3T subgroup was 4.3 mo in both
arms (HR1.04 [80% CI: 0.78, 1.41], p0.853). In the III- subgroup,
mPFS was 5.8 mo for Ixa/C vs. 5.3 mo for P/C (HR0.78 [80% CI: 0.55,
1.10]). Independent of treatment arm, mPFS for pts with 3T was 4.27 mo
[80% CI: 3.61, 5.42] and 5.59 mo (80% CI: 4.63, 6.47) for 3T- disease
(HR1.32 [80% CI: 1.06, 1.64]). IXA/C generally exhibited a similar safety
profile to P/C. Peripheral neuropathy (all grades, grade 3/4) was numerically
lower in the IXA/C arm (36.8%, 0%) vs. the P/C arm (56.3, 7.3%); however,
a higher incidence of grade 3/4 anemia and thrombocytopenia (16.7% and
15.6%, respectively) were observed in the IXA/C arm relative to P/C (0%
and 1.1%, respectively).
Conclusions: 1) IXA/C chemotherapy produced similar PFS and response as
P/C in 3T and 3T- subgroups. 2) There was no predictive value of 3T
for clinical activity (PFS or response) between IXA/C and P/C. 3) 3T
patients had worse PFS relative to 3T-, regardless of treatment. 4) IXA/C
was generally well tolerated in this study of first-line advanced NSCLC.
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The Influence of Epidermal Growth Factor Receptor Mutation
on the Outcomes of NSCLC Patient After Radiotherapy
Q.Pang1,2, R. Komaki1, J. L. Lo´pez Guerra1,3, D. Gomez1, Y. Zhuang1, S. H.
Lin1, M. S. O’Reilly1, J. D. Cox1, Z. Liao1, 1The University of Texas M.D.
Anderson Cancer Center, Houston, TX, 2Tianjin Medical University Cancer
Hospital, Tianjin, China, 3Virgen del Rocı´o University Hospital, Seville,
Spain
Purpose/Objective(s): Epidermal growth factor receptor (EGFR) mutations
are highly predictive of response to EGFR tyrosine kinase (TK) inhibitors in
advanced non-small-cell lung cancer (NSCLC). However, we know little
about the relationship between EGFR mutations and outcomes after radio-
therapy. The purpose of this study is to evaluate the influence of EGFR
mutation on outcomes of NSCLC after radiotherapy.
Materials/Methods:We retrospectively reviewed the pathological reports of
NSCLC patients who underwent both EGFR testing and primary tumor
radiotherapy between 2007 and 2009 in M.D. Anderson Cancer Center.
Nucleotide sequencing of the kinase domain of EGFR (exons 18-21) was
performed using nested PCR amplification of individual exons. Clinical
outcomes were measured by local control, distant metastasis, and overall
survival.
Results: There were 111 patients who underwent EGFR test as part of their
pathological diagnostic procedure. The distribution of stages was: stage I in
4, stage II in 18, stage III in 82, stage IV in 7 patients. The median volume
of gross tumor was 82.91cm3, and the median dose of radiotherapy was
64.21Gy. Seventy-seven patients received concurrent chemoradiotherapy.
The most common chemotherapy agents were carboplatin and etoposide.
Thirty-four patients received radiotherapy only; and 19 patients received
molecular targeted therapy including Tarceva. Among the 111 patients who
had EGFR test, 24 had EGFR mutations. There were 2 cases with mutations
in exon 18. Ten cases had mutation in exon 19 deletions. 1 case had mutation
in exon 20. Eleven cases had mutation in exon 21. For the whole group, a
presence of EGFR mutations was not associated with local control, distant
metastasis, or overall survival compared to the wild-type group (p0.6737,
p0.7355, p0.5623) respectively. Since most of the mutations (21/24)
were in exons 19 and 21, we also compared the difference of outcomes after
radiotherapy between these two groups. There were no differences in patient
demographics, including age, sex, stage, gross tumor volume, radiation dose,
or treatment with EGFR-TK inhibitor between the two groups. There were
significant differences between exon 19 group and exon 21 group in rates of
local recurrence (0/10 vs 7/11, p0.0021).There was no significant differ-
ence in distant metastasis and survival between the two groups (p0,0870;
p0. 9187).
Conclusion: The most common loci of EGFR mutations are in exons 19 and
21 respectively. NSCLC with EGFR mutation in the exon 19 had more
favorable disease control locally after radiotherapy. This finding, when
validated in larger studies, could be used as a prognostic factor in designing
personalize radiotherapy for NSCLC.
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PET/CT and Outcome in Lung Cancer Treated With Stereotac-
tic Body Radiation Therapy
J. Y. Chang, X. Zhang, R. Komaki, T. Pan, P. Allen, P. Balter, H. Chuang,
M.D. Anderson Cancer Center, Houston, TX
Purpose/Objective(s): Stereotactic body radiation therapy (SBRT) is be-
coming a standard treatment for medically inoperable stage I non-small cell
lung cancer (NSCLC). However, the role of PET/CT in predicting clinical
outcome after SBRT remains controversial, mainly because of residual PET
avidity after treatment. We analyzed the prognostic value of PET/CT stan-
dardized uptake values (SUVs) in stage I and isolated lung-recurrent NSCLC
treated with SBRT.
Materials/Methods: Patients with biopsy-proven stage I (n68) or isolated
lung parenchyma recurrent/secondary (n60) NSCLC were treated with
image-guided SBRT in an approved phase II clinical study. All patients
underwent disease staging with PET/CT followed by 4-dimensional CT-
based planning and daily CT-on-rail or cone-beam CT-guided SBRT. The
prescribed dose was 50 Gy to the planning target volume, delivered in 4
consecutive days. Follow-up care comprised CT and clinical examination
every 3 months for 2 years plus PET at 1-3 and 3.1-6 months and annually
thereafter.
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Results: At a median follow-up time of 18 months (range 6-56 months), the
local control rate for the treated lesion was 95.7%; rates of regional lymph
node recurrence and distant metastasis for the stage I group were 8.8% (6/68)
and 14.7% (10/68) and 12.5% and 28.1% for the recurrent-disease group.
Between lesions with or without local failure (LF), no difference was found
(p0.55) in mean SUVmax before SBRT (6.03.3 with LF vs.7.66.6
without LF, median 6.2 vs. 6.1), but post SBRT mean SUVmax differed
(p0.002), starting at 3.1-6 months after SBRT (SUVmax mean 6.42.2
with LF vs. 3.62.0 without LF; median 7.2 vs. 3) and continuing for up to
36 months. Seventeen patients (13.3%) developed a pseudo-tumor mass after
SBRT but those masses showed no increase in SUV and no recurrence with
serial follow-up. For the stage I group, a cutoff of 10 for SUVmax before
SBRT was predictive of overall survival (OS) (93.6% for SUV 10 vs.
43.9% for SUV 10 at 36 months, p0.017). Univariate analysis showed
preSBRT SUVmax and tumor histology (adenocarcinoma vs. squamous vs.
other NSCLC) to predict poor OS but not sex, age, race, performance status,
peripheral vs. central tumor location, or tumor size (2.5 vs. 2.5 cm).
Multivariate analysis confirmed that pre-SBRT SUVmax 10 was the
strongest predictor of poor OS (p0.031), followed by histology (p0.047).
Conclusions: High SUVs 3 months after SBRT are associated with local
recurrence in SBRT-treated lesions, and high (10) SUVs before SBRT
predict poor OS in patients with stage I NSCLC.
Author Disclosure Block: J.Y. Chang, None; X. Zhang, None; R.
Komaki, None; T. Pan, None; P. Allen, None; P. Balter, None; H.
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Treatment of Stage I NSCLC in Patients With Severe COPD:
Stereotactic Radiotherapy Outcomes and Systematic Review
D. Palma1, F. Lagerwaard1, G. Rodrigues2, C. Haasbeek1, S. Senan1, 1VU
University Medical Center, Amsterdam, Netherlands, 2London Regional
Cancer Program, London, ON, Canada
Purpose/Objective(s): Patients with severe COPD have a high risk of lung
cancer, and subsequently have a high risk of treatment complications. We
studied outcomes after stereotactic radiotherapy (SBRT) in patients with
severe COPD, and performed a systematic review of the literature on
outcomes after SBRT or surgery in these patients.
Materials/Methods: A single-institution cohort of 173 patients with COPD
GOLD III-IV and stage I NSCLC treated with SBRT was evaluated. A
systematic review identified studies reporting outcomes after SBRT or
surgery for stage I NSCLC in patients with COPD GOLD III-IV or a
predicted post-operative FEV1 of 40% or less. English-language studies
published after 1994 with at least 20 patients were included.
Results: In the single-institution cohort, median follow-up was 21 months
and median overall survival (OS) was 32 months. Actuarial 3-year local
control was 89%, and 1- and 3-year OS were 79% and 47%, respectively.
COPD severity correlated with OS (p0.01). The systematic review identi-
fied four other studies (two surgical, two SBRT, n196 patients). SBRT
studies were published more recently and included older patients than
surgical studies, and nearly all SBRT patients were medically inoperable.
Mean thirty-day mortality was 0% post-SBRT and 10% after surgery. Local
or loco-regional control was high (89% or more) after both treatments. After
SBRT, actuarial OS was 79-94% at 1 year and 43-70% at 3 years. Post-
surgical actuarial OS was 45-86% at 1 year and 31-66% at 3 years.
Conclusions: SBRT and surgery differ in risk of 30-day mortality in patients
with severe COPD. Despite the negative selection of SBRT patients, survival
at 1- and 3-years is comparable between the two treatments.
Author Disclosure Block: D. Palma, None; F. Lagerwaard, None; G.
Rodrigues, None; C. Haasbeek, None; S. Senan, Varian Medical Systems
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A Population-based Matched Pair Comparison of Stereotactic
Radiotherapy vs. Surgery for the Treatment of Stage I NSCLC
in Elderly Patients
D. Palma1, O. Visser2, F. Lagerwaard1, B. Slotman1, J. Belderbos3, S.
Senan1, 1VU University Medical Center, Amsterdam, Netherlands, 2Compre-
hensive Cancer Centre, Amsterdam, Netherlands, 3Netherlands Cancer In-
stitute, Amsterdam, Netherlands
Purpose/Objective(s): Treatment of stage I NSCLC in elderly patients is a
therapeutic challenge, and can be hampered by patient frailty, co-morbidity,
or concerns about toxicity. Up to 25% of Dutch patients with a stage I and
II NSCLC who are 75 years or older receive no oncological therapy at all
[Wouters M, 2010]. Stereotactic body radiation therapy (SBRT) is an
attractive treatment option for unfit and/or elderly patients, due to its ease of
administration and favorable toxicity profile. As data comparing surgery and
SBRT for elderly stage I NSCLC is lacking, we compared outcomes after
both treatments in North Holland.
Materials/Methods: A comprehensive population-based registry in North
Holland (www.ikcnet.nl/IKA), a region with a population of3 million, was
used to conduct a matched-pair analysis of overall survival after surgery vs.
SBRT for elderly patients (age 75 or older) diagnosed between 2005 and
2007. Surgery is the treatment of choice according to the treatment guide-
lines, and SBRT is preferred in case of medical inoperability. This popula-
tion-based registry was matched to institutional databases from centres
providing SBRT. Patients with clinical stage I were matched by age (3
years), T-stage, gender, and year of treatment. Baseline co-morbidities were
not available. Kaplan-Meier analysis was used to compare overall survival
(OS) outcomes.
Results: Between 2005 and 2007, 110 elderly patients with clinical stage I
disease were treated with surgery and 81 with SBRT; of these, 122 patients
could be matched (61 surgery, 61 SBRT). Median follow-up was 43 months.
In each group, median age at diagnosis was 79 years, 67% of patients were
male, and 64% had T1 disease. Most SBRT patients were medically inop-
erable. Thirty-day mortality was 8.2% (5 patients) after surgery and 1.6% (1
patient) after SBRT. OS at 1 year was 75% after surgery and 87% after
SBRT. At 3 years, OS was 60% after surgery and 41% after SBRT (log-rank
p0.16). Limiting the analysis only to the SBRT patients who had patho-
logical confirmation of their disease (46% of total) and their matches yielded
similar results, with no significant difference between treatment groups.
Conclusion: In this population-based matched-pair analysis of patients 75
years or older, there was no difference in OS between surgery or SBRT,
despite the fact that a large majority of SBRT patients were unfit for surgery
and controlling for co-morbidity was not possible.
Author Disclosure Block: D. Palma: None. O. Visser: None. F. Lager-
waard: None. B. Slotman: None. J. Belderbos: None. S. Senan: B.
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Presentation, Treatment and Survival Analysis of Patients 85
and Older with Non-small Cell Lung Cancer (NSCLC)
R. Ranck1, S. Subbiah1, A. Ganti2, P. T. Silberstein1, 1Creighton University
Hematology/Oncology, Omaha, NE, 2University of Nebraska Medical Cen-
ter, Omaha, NE
Purpose/Objective(s): In 2010, the American Cancer Society predicts there
will be a total of 222,520 new cases of lung cancer in the U.S. alone (1).
There have been very few studies looking at lung cancer presentation and
therapy in the elderly. One study found that most patients over the age of 65
with advanced NSCLC don’t receive chemotherapy even though it increases
median survival (3). Our study, to the best of our knowledge, is the first to
evaluate treatment patterns and results of NSCLC in patients over the age of
85. We looked further into this issue to examine how elderly patients present
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at diagnosis, their treatment options, and how this affects their median
survival.
Materials/Methods: 24,647 patients over the age of 85, including 137 over
the age of 100 were isolated from the SEER database that were diagnosed
with lung cancer between the years of 1988 and 2003. Many variables were
examined (including disease presentation, marital status, race, treatment
options, or refusal of treatment, and median survival) to find the key
differences between patients 85 and older and their younger counterparts.
Results: Those 85 and older received surgery less often (on average 3.9% of
stage III patients in the elderly vs. 20.4% of stage III in 0-84). Patients 85 and
older with stage I and stage II disease had surgery less frequently than those
less than 85 (22.8% compared to 66.51%). Patients over the age of 85 with
stage IV disease have a median survival of 2.3 months as compared to those
under the age of 85 of 4.5 months. Patients over the age of 85 who had
surgery lived on the average of 20 months as compared to those under 85
who lived 37 months. Patients over the age of 85 who had radiation lived on
the average 6.6 months as compared to those under the age of 85 who lived
9.1 months .Widowed elderly are more likely to refuse surgery (7.1%) than
the widowed 0-84 year olds (3.3%).
Conclusion: There are over 1000 patients each year diagnosed with NSCLC
who are over the age of 85. Approximately 20% receive surgery. The average
survivals of patients with NSCLC over the age of 85 compared to those
younger than 85 is markedly lower. Though patients who have surgery live
longer, most patients with stage I and II NSCLC over the age of 85 do not
have surgery.
(1) Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer
J Clin. 2010 Jul 7. Cancer Surveillance, Surveillance and Health Policy
Research, American Cancer Society, Atlanta, GA.
(2) Pearson, F Griffith. Non-small Cell Lung Cancer: Role of Surgery for
Stages I-III. Chest, Decemeber 1999; 116; 500S-503S.
(4) Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival
benefit in elderly patients with advanced non-small-cell lung cancer.
J Clin Oncol, May 2010; 28(13):2191-7.
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Targeted Therapy Against All Three VEGF Receptors by
Cediranib Enhances the Antitumor and Anti-metastatic Effects
of Paclitaxel and Radiation in an Orthotopic Human Lung
Cancer Model
O. Takahashi1, R. Komaki1, R. Tailor1, J. M. Ju¨rgensmeier2, A. Ryan2, P. D.
Smith2, J. J. Jacoby1, M. V. Korshunova1, R. S. Herbst1, M. S. O’Reilly1,
1Departments of Radiation Oncology and Thoracic/Head and Neck Medical
Oncology, the University of Texas MD Anderson Cancer Center, Houston,
TX, 2AstraZeneca, Alderly Park, United Kingdom
Purpose/Objective(s): Cediranib (RECENTIN™) is an orally active and
highly potent VEGF signaling inhibitor currently in Phase III development.
In the current study, we evaluated the therapeutic efficacy and radiosensi-
tizing effects of cediranib and paclitaxel in an orthotopic model of human
lung adenocarcinoma that mimics clinical patterns of malignant progression.
Materials/Methods: PC14PE6 human lung adenocarcinoma cells were in-
jected into the left lungs of nude mice. After 2 weeks, mice were randomized
(8/group) to treatment with vehicle control, cediranib (3 mg/kg/day po),
paclitaxel (200 g/week ip), radiation to the left lung and mediastinum (20
Gy in 5 fractions over 2 weeks), or radiation with cediranib and/or paclitaxel.
When controls demonstrated evidence of morbidity, all mice were sacrificed
and assessed for lung tumor burden and regional metastasis. Tumor tissues
were subjected to immunohistochemical analyses.
Results: All treatments were well tolerated. Radiation or cediranib mono-
therapy reduced median lung tumor volume by 80% (P0.0016) and 82%
(P0.0011), respectively, and mediastinal metastasis and prevented pleural
effusion. Paclitaxel reduced median tumor volume by 33% with only a
modest effect on metastasis and pleural effusion. The effects of radiation
therapy were marginally improved by paclitaxel. Cediranib substantially
enhanced the antitumor and anti-metastatic effects of radiation therapy with
a reduction in median primary tumor volume of 99.8% (P0.0006) and left
lung weight of 93% (P0.0007), versus control, and a near complete block
of metastasis (P0.0098). Trimodality therapy resulted in the near complete
prevention of lung tumor growth and metastasis. Immunohistochemical
analyses of lung tumors revealed that radiation or cediranib reduced mi-
crovessel density and tumor cell proliferation and increased tumor and
endothelial cell apoptosis, with little effect upon the expression of VEGF or
VEGFR2. The antiangiogenic and apoptotic effects, but not the anti-prolif-
erative effects, were substantially enhanced for combined modality therapy.
Conclusions: Cediranib inhibited tumor growth and metastasis and enhanced
the effects of radiation therapy in an orthotopic lung cancer model, with
radiosensitizing effects that were superior to paclitaxel. Trimodality therapy
with radiation, cediranib and paclitaxel, resulted in the near complete
suppression of lung tumor growth and metastasis with markedly enhanced
antiangiogenic and apoptotic effects but only marginally improved inhibition
of tumor cell proliferation. These data provide a strong basis for the
development of clinical trials combining cediranib, radiation and paclitaxel
in lung cancer patients.
Author Disclosure Block: O. Takahashi, None; R. Komaki, None; R.
Tailor, None; J.M. Ju¨rgensmeier, None; A. Ryan, None; P.D. Smith,
None; J.J. Jacoby, None; M.V. Korshunova, None; R.S. Herbst, Astra-
Zeneca, C. Other Research Support; M.S. O’Reilly, AstraZeneca, F. Con-
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FDG-PET vs. Histologic Staging of the Mediastinum in Patients
With Pathologic N0-1 Non-small Cell Lung Cancer (NSCLC):
What Should Be the Gold Standard?
L. Xie1,2, M. Saynak3, W. Chiu4, J. E. Bailey1, D. V. Fried1, N. K.
Veeramachaneni5, J. L. Hubbs1, R. H. Feins5, B. F. Qaqish4, L. B. Marks1,
1Department of Radiation Oncology, University of North Carolina at Chapel
Hill, Chapel Hill, NC, 2Department of Radiation Oncology, Fudan Univer-
sity Cancer Center, Shanghai, China, 3Department of Radiation Oncology,
Trakya University Hospital, Edirne, Turkey, 4Department of Biostatistics,
School of Public Health, University of North Carolina at Chapel Hill, Chapel
Hill, NC, 5Department of Surgery, Division of Cardiothoracic Surgery,
University of North Carolina at Chapel Hill, Chapel Hill, NC
Purpose/Objective(s): Histological evaluation of the mediastinum is typi-
cally taken as “gold standard” for staging cancer. When there are discrep-
ancies between PET and histology, treatment recommendations are typically
based on histology. In order to further evaluate this issue, we assess
prognostic implications of mediastinal PET findings in patients undergoing
curative resection of NSCLCa with histologically negative mediastinal
nodes.
Materials/Methods: We reviewed records of patients with a pre-operative
PET undergoing curative surgery for pathologic T1-3N0-1 NSCLCa at
University of North Carolina from 1996-2006. Those receiving post-opera-
tive RT were excluded. Local-regional/distant failure rates in patients with or
without mediastinal abnormalities on pre-operative PET were compared via
binary logistic regression, and event-free survivals (i.e. failures) were com-
pared with log-rank tests. Cox regression was used for multivariable analysis.
Results: Ninety-two patients were evaluable (all histologically negative in
mediastinum; 42 via mediastinoscopy); 17 with a positive PET in mediasti-
num, and 75 normal in mediastinum. Median follow-up for event-free
survivors was 29 months (range 1-77). These two groups were similar in rate
of receipt of adjuvant chemotherapy (18% 3⁄17 vs 13% 10⁄75). The rates of
local-regional failure were 59% (10/17) in patients with positive PET in
mediastinum, vs. 15% (11/75) in those with normal PET (p0.001, OR: 8.3;
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95% CI: 2.6-26.5). Most of the failures were in pN1 patients. The rates of
distant failure were also higher in PET positive group (47.1% vs. 9.3%,
p0.001; OR: 8.6, 95% CI: 2.5-29.5). Compared to PET positive in medi-
astinum, PET negative group was associated with a significantly better local
failure-free survival (P0.001), as well as distant failure-free survival
(P0.001). In multivariable analysis (also considering primary tumor size,
sampled N2 station number, and chemotherapy), PET-findings in mediasti-
num remained prognostic for both localregional failure (p0.001, HR: 4)
and distant failure (p0.001, HR: 6).
Conclusions: The presence of a positive mediastinum on pre-operative PET
appears to have prognostic implications despite the mediastinal lymph nodes
being negative histologically. The high rate of local-regional failure suggests
that post-operative RT and/or chemotherapy may be particularly helpful in
patients with a positive mediastinum on pre-operative PET. Prospective
studies may better clarify the implications of a positive PET in mediastinum
in patients with histologically-negative mediastinal nodes. Further evaluation
of subsets (e.g. pN0 vs pN1 and /- mediastinoscopy) and biases in
treatment selection that may have influenced the analysis will be presented.
Author Disclosure Block: L. Xie: None. M. Saynak: None. W. Chiu:
None. J.E. Bailey: None. D.V. Fried: None. N.K. Veeramachaneni: None.
J.L. Hubbs: None. R.H. Feins: None. B.F. Qaqish: None. L.B. Marks:
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A Pooled Exploratory Analysis of the Effect of Tumor Size on
Survival Benefit from Adjuvant Platinum-based Chemotherapy
(ACT) in Node Negative (N0) Non-small Cell Lung Cancer
(NSCLC)
S. Cuffe1, M. Ezzalfani2, S. Graziano3, J. Pignon2, L. Seymour4, E. Strevel5,
R. Burkes6, F. A. Shepherd1, 1Princess Margaret Hospital, Toronto, ON,
Canada, 2Institut Gustave-Roussy, Villejuif, France, 3State University of
New York Upstate Medical University, New York, NY, 4NCIC Clinical Trials
Group, Kingston, ON, Canada, 5The Credit Valley Hospital, Mississauga,
ON, Canada, 6Mount Sinai Hospital, Toronto, ON, Canada
Purpose/Objective(s): Retrospective subset analyses of JBR.10 and
CALGB-9633 suggest a survival benefit for ACT only in stage IB NSCLC
tumors 4cm. However, neither the 6th nor 7th editions of TNM classifica-
tion recognize this cut-point. The 7th edition classifies tumors as T2a
(3–5cm), T2b (5–7cm) and T3 (7cm), with T2bN0 stage IIA and
T3N0 IIB. It is unknown whether the new T-descriptors identify differential
survival benefit from ACT. The aim of this study is to explore the effect of
new T-descriptors on survival benefit from ACT in N0 NSCLC in JBR.10
and CALGB-9633. We will also evaluate the prognostic effect of T-
descriptors on overall (OS) and disease-free survival (DFS).
Materials/Methods: Individual patient data including tumor size and sur-
vival were collected for N0 patients in JBR.10 (n218) and CALGB-9633
(n330). Patients were reclassified by T-size as T2a, T2b, T3 or T3cm
(T3cm with other T2 characteristics). Chemotherapy and control arms
were compared using intention-to-treat analysis. Log-rank stratified by trial
and Cox model stratified by trial and adjusted for age, sex, PS, histology and
surgical procedure were used for survival analyses. Chi2 tests were used
to study heterogeneity. T-size-by-treatment variation on survival was
studied using interaction tests and tests for trend. Prognostic value of
T-size was analyzed using both control and chemotherapy arms stratified
by trial and arm.
Results: We report results from JBR.10. Updated pooled analysis with
CALGB-9633 will be reported after pathology review and confirmation of
T-status. Among 218 N0 JBR.10 patients, 128 (59%) were T2a, 38 (17%)
T2b, 19 (9%) T3 and 33 (15%) T3cm (pleural involvement or proximal
bronchus location). There was an imbalance between groups with respect to
treatment, with T3cm patients less likely to receive chemotherapy
(p0.011). Larger tumors more often required pneumonectomy (p0.0005),
but baseline characteristics were otherwise similar. T-size was significantly
prognostic for DFS (test for trend, p0.02) but not OS (p0.11) on
multivariate analysis, although there was a trend for shorter OS as tumor size
increased. Compared to T2a patients, the HR for OS was 0.6 for T3cm (CI:
0.3-1.3), 1.1 for T2b (0.6-2.1) and 1.4 for T3 (0.7-3.1). There was no
significant association between T-size and survival benefit from ACT with
HRs of 0.6 for T3cm (0.1-5.2), 1.2 for T2a (0.6-2.2), 0.3 for T2b (0.1-1.2)
and 0.9 for T3 (0.2-4.4; p0.52).
Conclusions: Final conclusions concerning benefit from ACT in node
negative T-stage subsets await the addition of the CALGB patients to this
analysis. Supported by French Cancer League, Sanofi-Aventis, National
Cancer Institute and Canadian Cancer Society Research Institute.
Author Disclosure Block: S. Cuffe: None. M. Ezzalfani: None. S. Gra-
ziano: None. J. Pignon: None. L. Seymour: None. E. Strevel: None. R.
Burkes: None. F.A. Shepherd: None.
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Staging Implications of Intraoperative Ultrasound Guided Me-
diastinal Lymphadenectomy in Non-small Cell Lung Cancer
Surgery
N. Ilic, J. Juricic, J. Banovic, D. Krnic, I. Peric, N. Frleta Ilic, University
Surgical Hospital, Split, Croatia
Purpose/Objective(s): The extend of lymph node involvement in patients
with non-small cell lung cancer (NSCLC) is the cornerstone of staging and
influences both multimodality treatment and final outcome. We studied
safety, accuracy and characteristics of intraoperative ultrasound (US) guided
systematic mediastinal nodal dissection in patients with resected NSCLC.
Materials/Methods: Prospective randomized trial of intraoperative surgical
staging after radical surgery for NSCLC was carried out. Intraoperative hand
held ultrasound probe was used in systematic mediastinal nodal dissection in
124 patients after radical surgery for NSCLC and compared with 120 patients
who underwent lung resections and standard systematic mediastinal nodal
dissection. Mapping of the lymph nodes by their number and station
followed by histopathologic evaluation was performed. Patients data were
statistically analyzed.
Results: The surgical procedure used depended on the extent of the
disease, as well as the cardiopulmonary reserve of the patients and was
comparable in both groups of patients. Operating time was prolonged for
12(6–20) minutes in patients with US guided mediastinal nodal dissec-
tion, but number and stations of evaluated lymph nodes was significantly
higher (p0.001) at the same group of patients. Skip nodal metastases
were found in 24% of patients without N1 nodal involvement. We
upstaged 22 (10%) patients using US guided mediastinal lymphadenec-
tomy. Median follow-up was 38 (range, 10–52) months. Standard staging
system seemed to be improved in US guided mediastinal lymphadenec-
tomy patients. Complications rate showed no difference between ana-
lyzed groups of patients.
Conclusions: Higher number and location of analyzed mediastinal nodal
stations in patients with resected NSCLC using hand held ultrasound probe
suggested to be of great oncology significance. Procedure showed absolute
safety and high accuracy. Our results indicated that intraoperative US may
have important staging implication. Further clinical studies should be carried
out in order to improve intraoperative staging in NSCLC patients.
Author Disclosure Block: N. Ilic, None; J. Juricic, None; J. Banovic,
None; D. Krnic, None; I. Peric, None; N. Frleta Ilic, None.
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Bax and Bcl-2 Expression in Neuroendocrine Carcinoma of the
Lung and Potential for New Therapeutic Target
M. Batus, D. C. McFarland, J. Coon, M. Pool, K. Walters, S. Basu, M. J.
Fidler, P. Bonomi, Rush University Medical Center, Chicago, IL
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Purpose/Objective(s): Only minimal advances have been made in the
treatment of neuroendocrine cancers (NECs) including small cell lung cancer
(SCLC). Molecular markers may allow us to identify patients most likely to
benefit from new treatment options and drug combinations. High Bcl-2
expression has previously been reported to predict worse outcome in SCLC.
The objective of our study was to determine the frequency and potential
prognostic significance of Bcl-2 and Bax expression in neuroendocrine
tumors.
Materials/Methods: Tissues from 150 patients with neuroendocrine carci-
noma were stained for multiple molecular markers including Bcl-2 and Bax.
Frequency and intensity of expression were measured on a scale of 0–4 (freq
0no expression, freq 11–10%, freq 211–35%, freq 336–70%, freq
471–100%). Tumor marker frequency and intensity were assimilated as a
product of the two on a scale of 0–16. The ratio of the Bcl-2 and Bax
products was calculated. Charts were retrospectively reviewed for stage,
performance status, date of diagnosis/death, survival, and treatment (type,
dates, response).
Results: Of the original 150 tissue samples, 112 were analyzed for Bcl-2
frequency, 73% expressed frequency of 1 or greater; pts with Bcl-2 fre-
quency 3 had significantly shorter median OS (162.1 vs. 58.1 weeks)
(p0.0197). 124 samples were analyzed for Bax frequency; 41% expressed
frequency of 2 or greater with a median OS of 45.5 weeks vs. 57.8 weeks
(p0.0273). Bcl-2/Bax product ratio under 1.5 resulted in OS of 44.2 weeks
vs. 63.7 weeks for product ratio over 1.5 (p0.0261).
Conclusions: Our retrospective study revealed significantly shorter OS
associated with higher frequency of Bcl-2 expression which was expected
given its anti-apoptotic role. Bax expression was hypothesized to confer
greater OS given its pro-apoptotic properties but instead higher Bax fre-
quency was associated with shorter OS. These results were confirmed by the
Bcl-2/Bax product ratio, where increased Bax product was associated with
shorter OS. This suggests that Bax is not playing a decisive pro-apoptotic
role in SCLC. The basis for its seemingly paradoxical association with
shorter survival is under study.
Author Disclosure Block: M. Batus: None. D.C. McFarland: None. J.
Coon: None. M. Pool: None. K. Walters: None. S. Basu: None. M.J.
Fidler: None. P. Bonomi: None.
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Survival Among Smokers and Nonsmokers in the National
Comprehensive Cancer Network (NCCN) Non-small Cell Lung
Cancer (NSCLC) Cohort
A. K. Ferketich1, J. C. Niland2, R. Mamet2, C. Zornosa3, T. A. D’Amico4,
D. S. Ettinger5, G. P. Kalemkerian6, K. M. Pisters7, M. E. Reid8, G. A.
Otterson9, 1The Ohio State University College of Public Health and Com-
prehensive Cancer Center – James Cancer Hospital and Solove Research
Institute, Columbus, OH, 2City of Hope, Los Angeles, CA, 3NCCN, Fort
Washington, PA, 4Duke Comprehensive Cancer Center, Durham, NC, 5The
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore,
MD, 6University of Michigan Comprehensive Cancer Center, Ann Arbor, MI,
7The University of Texas MD Anderson Cancer Center, Houston, TX,
8Roswell Park Cancer Institute, Buffalo, NY, 9The Ohio State University
College of Medicine and Comprehensive Cancer Center – James Cancer
Hospital and Solove Research Institute, Columbus, OH
Purpose/Objective(s): There is a growing body of literature linking contin-
ued smoking with poor outcomes among lung cancer patients, including
greater symptom burden, complications from surgery, progression of disease,
and mortality. The objectives of this study were to compare the survival
times among current smokers, former smokers, and never smokers overall
and among patients who received surgery or drug therapy, separately.
Materials/Methods: The study cohort consisted of patients who presented to
one of the NCCN member institutions participating in the NSCLC Database
Project and who consented to be in the database. Current, former and never
smokers were compared with respect to overall survival using the Kaplan-Meier
method. Cox proportional hazards models were fit and hazard ratios (HR) and
95% confidence intervals (CI) were estimated among the smoking groups.
Confounding variables, such as center, age, sex, comorbidity, histology and, in
some models, stage, were included in the models as covariates. The proportional
hazards assumption was checked with plots and statistical tests.
Results: A total of 2,483 patients diagnosed with NSCLC were included in
the analysis; 32.8% were current smokers, 12.8% were never smokers,
52.7% were former smokers and 1.7% had unknown smoking status. The
average age at diagnosis was 64 years and 49% of participants were male.
Most patients had advanced stage disease, 27% were stage I or II, 27% were
stage III, and 46% were stage IV. With respect to survival, among stage I and
II patients, current and never smokers were not significantly different;
however, current smokers had an increased risk of death compared to former
smokers (HR 1.55, 95% CI: 1.06-2.26). Among stage III patients, current
smokers had an increased risk of death compared to never smokers (HR 1.66,
95% CI: 1.11-5.22), but the difference between current and former smokers
was not significant (HR 1.23, 95% CI: 0.96-1.57). Among stage IV patients,
current smokers had significantly poorer survival compared to never (HR
1.84, 95% CI: 1.46-2.33) and former (HR 1.24, 95% CI: 1.06-1.44) smokers.
Similar results were found for patients who received drug therapy, stratified
by stage. Among all patients who underwent surgery, the three smoking
groups were not significantly different with respect to survival after control-
ling for confounding variables, including stage.
Conclusions: Among stage III and IV patients, current smokers had poorer
survival than never smokers and, among stage I-II and IV patients, current
smokers had an elevated hazard of all-cause mortality compared to former
smokers. While we could not examine the impact of the length of smoking
cessation on survival, these results suggest that smokers who are diagnosed
with NSCLC should be encouraged to quit.
Author Disclosure Block: A.K. Ferketich: None. J.C. Niland: None. R.
Mamet: None. C. Zornosa: None. T.A. D’Amico: None. D.S. Ettinger:
None. G.P. Kalemkerian: None. K.M. Pisters: None. M.E. Reid: None.
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Lung-sparing Ambulatory Repeated Intrapleural Chemother-
apy Plus Intrapleural P-32 Isotope Radiation for Malignant
Pleural Mesothelioma
J. R. Sonett1, M. E. Ginsburg1, J. Javidfar1, R. Fawwaz2, E. Hare3,
C. Visser3, G. Leinwand3, M. Hesdorffer3, R. N. Taub3, 1NYPH/Columbia-
,Thoracic Surgery Dept, NYC, NY, 2NYPH/Columbia, Radiology Depart-
ment, NYC, NY, 3NYPH/Columbia, Mesothelioma Center, NYC, NY
Purpose/Objective(s): Extirpative lung or pleural surgery has had only
limited success in the treatment of malignant pleural mesothelioma, and is
not suitable for many patients. We have therefore investigated a lung-sparing
regimen of repeated courses of ambulatory intrapleural chemotherapy fol-
lowed by intrapleural radioactive Phosphorus-32 in patients with early stage
malignant pleural mesothelioma.
Materials/Methods: At initial videothoracoscopy two modified intrapleural
catheters were placed, anteriorly from the ipsilateral lung apex along the
pericardial border, and posteriorly into and along the diaphragmatic sulcus.
Each was attached to a subcutaneous mediport chamber placed over the
ipsilateral lower ribs. Fixed doses of intrapleural cisplatin 50 mg and/or
Doxorubicin 20 mg, with or without gamma interferon (1000 micrograms)
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was injected at 1–2 week intervals into both ports to perfuse the entire pleural
space. The distribution of injectate was verified by intracavitary iohexol CT
imaging. Additional intravenous pemetrexed plus cisplatin or carboplatin
was given to selected patients. At week 8–12 in selected patients, the pleural
cavity was imaged with radioactive Technetium-labelled sulfur colloid; if
uniformly distributed, 15 mCi of radioactive p32 chromic phosphate sulfur
colloid was injected, thereby delivering 4000–6000 cGy to accessible
pleural surfaces. The catheters were subsequently removed and pleural
surfaces inspected and biopsied at second-look videothoracoscopy.
Results: The above procedures were well tolerated without early or late
complications. Twenty one (21) patients, 17 males and 4 females aged 46–79
were treated, six with both peritoneal and pleural involvement. Eight patients
received intrapleural P32. Patients have been followed for 4–45 months.
Eleven patients (including one who underwent EPP) died of progressive
disease at 5–28 months. Ten patients are alive, eight with disease; of the
latter two have had EPP and two have undergone pleurectomy/decortications
to treat recurrent/persistent disease. Surgical pleurectomy/decortication or
extrapleural pneumonectomy remain possible options in four other treated
patients.
Conclusions: Lung-sparing repeated intrapleural chemotherapy combined
with potentially effective doses of intrapleural irradiation is a feasible
additional option, with or without extirpative surgery and systemic chemo-
therapy, for selected patients with malignant pleural mesothelioma.
Author Disclosure Block: J.R. Sonett: None. M.E. Ginsburg: None. J.
Javidfar: None. R. Fawwaz: None. E. Hare: None. C. Visser: None. G.
Leinwand: None. M. Hesdorffer: None. R.N. Taub: None.
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Impact of AKT Inhibition and HGF Stimulation on Erlotinib
Efficacy in NSCLC Cell Lines
P. C. Mack, N. Farneth, C. M. Mahaffey, W. S. Holland, P. N. Lara, D. R.
Gandara, UC Davis Cancer Center, Sacramento, CA
Purpose/Objective(s): Potential mechanisms of acquired resistance to erlo-
tinib include aberrant activation of alternative receptor tyrosine kinases
and/or their downstream signaling components, including the Met receptor,
its ligand (HGF) and the signal transduction intermediary AKT. Strategies to
overcome inherent resistance mechanisms, or prevent the emergence of
acquired resistance, are vital to fully realizing the therapeutic potential of
EGFR tyrosine kinase inhibitors such as erlotinib. We therefore investigated
the opposing effects of HGF stimulation and AKT inhibition on erlotinib
activity in NSCLC cell lines.
Materials/Methods: AKT inhibition was achieved using the selective allo-
steric AKT inhibitor MK-2206 (Merck), and Met inihibition by PHA665752.
The addition of exogenous recombinant HGF was used to stimulate Met.
Using a panel of well-characterized NSCLC cell lines with diverse oncogenic
mutation profiles, erlotinib activity was assessed in the presence or absence
of kinase inhibition and/or HGF. Cell lines were chosen that ranged in
sensitivity to erlotinib from highly sensitive to highly resistant. Treatment
activity was assessed by growth assays (MTT, colony formation), apoptosis
(PARP and caspase cleavage, subG1 content), cell cycle analysis (flow
cytometry), RT-PCR and Western blotting.
Results: In erlotinib-sensitive cell lines, HGF supplementation largely re-
versed the cytostatic and cytotoxic effects of erlotinib. This was particularly
evident in the EGFR-mutant HCC827 line, where HGF protected cells from
extensive growth inhibition and apoptosis normally induced by erlotinib
(p0.0001). HGF also induced Met phosphorylation and modulated expres-
sion of downstream apoptotic mediators including Bim. HGF-mediated
resistance was partially abrogated by the AKT inhibitor MK2206 and
completely abrogated by the Met inhibitor PHA665752. MK2206 was
additive or synergistic with erlotinib treatment in all cell lines tested,
including those resistant to single-agent erlotinib. In contrast, PHA665752
activity was only evident in terms of reversing HGF-mediated resistance.
Long-term growth assays showed that the addition of MK2206 to erlotinib
substantially reduced the number of surviving colonies.
Conclusions: These results suggest that the AKT inhibitor MK2206 can
augment activity of erlotinib, partially overcoming both acquired and pri-
mary resistance mechanisms. Met inhibition was able to completely override
HGF-mediated resistance. These data have implications for optimization of
erlotinib-based therapy in NSCLC.
Author Disclosure Block: P.C. Mack, None; N. Farneth, None; C.M.
Mahaffey, None; W.S. Holland, None; P.N. Lara, None; D.R. Gandara,
None.
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Biomarker Analyses from the Phase III, Randomized, Open-
label, OPTIMAL Study of First-line Erlotinib Versus Carbopla-
tin (CBDCA) Plus Gemcitabine (GEM) in Chinese Patients (pts)
With Advanced Non-small Cell Lung Cancer (NSCLC) Whose
Tumors Harbor Activating EGFR Mutations. On Behalf of the
OPTIMAL Investigators
X. Liu1, Y. Wu2, C. Zhou3, S. Lu4, L. Zhang5, X. Zhi6, Y. Cheng7, L. Chen8,
Y. Luo9, C. Hu10, 1307 Hospital of PLA, Beijing, China, 2Guangdong Lung
Cancer Institute, Guangdong General Hospital (GGH), Guangdong, China,
3Shanghai Pulmonary Hospital, Tongji University, Shanghai, China,
4Shanghai Chest Hospital, Shanghai, China, 5Cancer Center of Sun Yat-Sun
University, Guangzhou, China, 6Xuanwu Hospital of Capital Medical Uni-
versity, Beijing, China, 7Jilin Province Cancer Hospital, Changchun, China,
8Cancer Hospital Shantou University Medical College, Shantou, China,
9Hunan Province Tumor Hospital, Changsha, China, 10The Second Xiang-ya
Hospital, Changsha, China
Purpose/Objective(s): A phase II study (Rosell et al, 2010) showed the
promising efficacy of erlotinib in pts with advanced NSCLC whose tumors
harbor activating EGFR mutations (mut ve). The multicenter phase III
OPTIMAL trial was initiated to compare erlotinib monotherapy with che-
motherapy as first-line therapy for EGFR mut ve advanced NSCLC, and
included additional biomarker analyses to identify any correlation with
clinical outcomes.
Materials/Methods: 165 chemotherapy-naı¨ve Chinese pts with advanced
NSCLC whose tumors had exon 19 deletions or L858R exon 21 mutations of
EGFR were enrolled and randomized to receive either erlotinib (150mg/d)
until disease progression or unacceptable toxicity, or GEM (1000mg/m2
d1  d8) plus CBDCA (AUC5, d1) for up to 4 cycles. The primary
endpoint was progression-free survival (PFS), and secondary endpoints
included overall survival (OS), objective response rate (ORR), safety, quality
of life (QoL) and biomarker analyses. Of the 83 pts in the erlotinib arm, 70
had sufficient diagnostic tumor samples available to carry out further bi-
omarker analyses at baseline. Analyses for KRAS, EGFR T790M, PI3K and
PTEN mutations were carried out using DNA sequencing, and C-MET
amplification was assessed using quantitative polymerase chain reaction
(Q-PCR); all analyses were conducted in a central laboratory.
Results: No KRAS mutations were identified in the 70 evaluable pts. A
T790M mutation was detected in 1 pt (1.4%). The degree of C-MET
amplification was assessed in 67 evaluable pts, with an amplification rate of
5.9%. Further analyses are being conducted, including correlations with
clinical outcomes, and the full results will be reported at the meeting.
Conclusions: As expected, KRAS mutations were not seen concurrently with
EGFR mutations. The degree to which secondary biomarkers play a role in
the efficacy outcomes with erlotinib therapy in activating EGFR mut ve
disease will be shown by the full biomarker analyses, which will be
presented.
Author Disclosure Block: X. Liu, None; Y. Wu, F. Hoffmann-La Roche, C.
Other Research Support; F. Hoffmann-La Roche, D. Speaker’s Bureau/
Honoraria; C. Zhou, F. Hoffmann-La Roche, D. Speaker’s Bureau/Hono-
raria; S. Lu, None; L. Zhang, AstraZeneca, C. Other Research Support;
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Overall Survival and Progression Free Survival Results for a
Randomized Phase 2 Trial of Ipilimumab (IPI) and Paclitaxel/
Carboplatin (P/C) in First-Line Stage IIIb/IV Non-small Cell
Lung Cancer (NSCLC)
T. J. Lynch1, J. Neal2, I. Bondarenko3, A. Luft4, P. Serwatowski5, F. Barlesi6,
R. Chacko7, M. Sebastian8, J. Cuillerot9, M. Reck10, 1Yale Cancer Center
and Smilow Cancer Hospital, New Haven, CT, 2Massachusetts General
Hospital Cancer Center, Boston, MA, 3Clinical Hospital Dnipropetrovsk,
Dnepropetrovsk, Ukraine, 4Leningrad Regional Clinical Hospital, St. Pe-
tersburg, Russian Federation, 5Oddzial Chemioterapii, Szczecin, Poland,
6University of Mediterranee, Assistance publique Hopitaux de Marseille,
Marseille, France, 7Christian Medical College, Vellore, India, 8Universita-
etsmedizin Mainz, Mainz, Germany, 9Bristol-Myers Squibb Research and
Development, Wallingford, CT, 10Hospital Grosshansdorf, Grosshansdorf,
Germany
Purpose/Objective(s): IPI is a fully human monoclonal antibody that po-
tentiates immune response by inhibiting CTLA-4. CA184-041 is a double-
blind, randomized phase 2 study of IPI combination with P/C in chemother-
apy naı¨ve recurrent/metastatic lung cancer.
Materials/Methods: 204 pts were randomized 1:1:1 to receive: IPI 
concurrent schedule (CON) IV P/C (N70), IPI  phased schedule (PHA)
P/C (N68), or P/C alone (PBO) (N66). IPI was administered at 10 mg/kg
every 3weeks (wks) starting with cycle (c) 1  4 (CON) or starting with c
3 4 (PHA) then every 3 months. P/C was given as 175 mg/m2 and AUC6
every 3wks  6. Efficacy was assessed by immune-related response criteria
(irRC) and mWHO. The primary endpoint compared immune-related PFS
(irPFS) between CON vs PBO and PHA vs PBO. One-sided log-rank test
(0.10) used to calculate statistical significance.
Results: Baseline characteristics were generally balanced. Ipilimumab in
combination with P/C extended median irPFS for both the CON (5.52 mo
[95% CI: 4.17, 6.74], p0.094, HR0.775 [95% CI: 0.53, 1.13] and PHA
regimens (5.68 mo [95% CI: 4.76, 7.79], p0.026, HR0.686 [95% CI:
0.47, 1.01]) compared to P/C alone (4.63 mo [95% CI: 4.14, 5.52]). IPI plus
P/C extended mWHO PFS in the PHA arm only compared to P/C alone (5.13
mo [95% CI: 4.17, 5.72], p0.024, HR0.691 [95% CI: 0.48, 1.00] vs. 4.21
mo [95% CI: 2.76, 5.32]). Interim median OS trended in favor of the IPI arm
for the PHA regimen (11.56 mo [95% CI: 9.26, 14.39], p0.104, HR0.748
[95% CI: 0.48, 1.18]) compared to P/C alone (9.99 mo [95% CI: 6.97, 13.63].
IPI in combination with P/C did not appear to significantly extend interim
median OS for the CON regimen (11.01 mo [95% CI: 8.38, 12.75], p0.429,
HR0.962 [95% CI: 0.63, 1.48]) compared to P/C alone 11.56 mo (95% CI:
9.26, 14.39). Final OS results will be presented. IPI  P/C was generally
well tolerated. Total gr 3/4 irAEs (pruritis, rash, alopecia, diarrhea, colitis)
were 20% and 15% for CON and PHA regimens, respectively; and were
reversible in most cases. Gr 5 toxic epidermal necrolysis was seen in 1 pt for
CON.
Conclusion: Ipilimumab in combination with P/C met its primary endpoint
by demonstrating superiority in irPFS compared with P/C alone with con-
sistent findings across other efficacy endpoints. The PHA regimen appeared
to demonstrate better efficacy than the CON regimen. Ipilimumab did not
increase P/C related toxicity. These results support further study of ipili-
mumab in NSCLC.
Author Disclosure Block: T.J. Lynch, Bristol-Myers Squibb, F. Consult-
ing/Advisory Board; J. Neal, None; I. Bondarenko, None; A. Luft, Bristol-
Myers Squibb, B. Research Grant; P. Serwatowski, None; F. Barlesi,
Bristol-Myers Squibb, B. Research Grant; R. Chacko, None; M. Sebastian,
None; J. Cuillerot, Bristol-Myers Squibb, A. Employment; Bristol-Myers
Squibb Stock, E. Ownership Interest; M. Reck, Hoffmann-La Roche, D.
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Zeneca, D. Speaker’s Bureau/Honoraria; Merck, D. Speaker’s Bureau/Hon-
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Bevacizumab (BV) Treatment to Progression (BTP) in Non-
small Cell Lung Cancer (NSCLC): Outcomes From a US Com-
munity Practice Network
E. Nadler1, E. Yu2, A. Ravelo2, A. Sing2, M. Forsyth3, S. Gruschkus3, 1Texas
Oncology - Baylor Sammons Cancer Center, Dallas, TX, 2Genentech, South
San Francisco, CA, 3Healthcare Informatics, a service of US Oncology, The
Woodlands, TX
Purpose/Objective(s): BV (Avastin®) extends progression-free (PFS) and
overall survival (OS) when combined with 1st line (1L) chemotherapy (CT)
and continued as monotherapy to progression (PD) in the treatment of
nonsquamous (ns) NSCLC. In US clinical practice, BV is often not admin-
istered until PD and is discontinued at the same time as CT. A retrospective
analysis of US Oncology Network’s electronic medical records describes
PFS and OS among ns NSCLC patients receiving BTP after 1L CT  BV.
Materials/Methods: Patients with NSCLC treated 7/1/06–6/30/08 were
analyzed as 2 cohorts based on continuing BV until PD after completion of
CT (BTP) or not (No BTP). Multivariate analyses estimated hazard ratios of
PFS and OS using Cox proportional hazards, adjusting for age, gender, stage
at diagnosis (dx), performance status (KPS), BMI, baseline hemoglobin,
number of CT cycles, and BV dose. To control for survivorship bias, patients
with PD or death within 30 days of CT completion were excluded and
landmark analyses were conducted at 18, 21 and 26 wks from initial
Treatment. Residual PFS and OS are defined as the time from the landmark
to escalation in line of therapy and the time from the landmark to death,
respectively.
Results: 403 ns NSCLC patients received 1L CT  BV; 154 BTP, 249 No
BTP. Baseline characteristics were generally similar between BTP and No
BTP groups: age (46 vs 44y), female (66 vs 67%), dx stage IIIB–IV (79 vs
80%), and KPS 100–80 (81 vs 76%). The BTP group had longer OS and PFS
compared to the No BTP group (median OS  20.9 vs 10.2 mos; median
PFS  10.3 vs 6.5 mos). In the landmark analyses, BTP was associated with
improved Residual OS at Wks 18, 21 and 26 and improved Residual PFS at
Wk 18 compared to No BTP. Hazard ratios for OS were 0.54 (95% CI,
0.34–0.86) at Wk 18, 0.58 (95% CI, 0.35–0.94) at Wk 21, and 0.61 (95% CI,
0.37–0.98) at Wk 26. Hazard ratio for PFS was 0.73 (95% CI, 0.56–0.96) at
Wk 18.
Conclusions: In this retrospective analysis of 1L ns NSCLC patients receiv-
ing care in a community setting, patients receiving BTP had longer PFS and
OS relative to a group of concurrently treated patients not receiving BTP.
While a direct causal relationship cannot be determined, these results support
the importance of continuing VEGF suppression to optimize outcomes in
patients with ns NSCLC.
Author Disclosure Block: E. Nadler: None. E. Yu: A. Employment;
Genentech. ; E. Ownership Interest; Roche Holdings. A. Ravelo: A. Em-
ployment; Genentech. ; E. Ownership Interest; Roche Holdings. A. Sing: A.
Employment; Genentech. ; E. Ownership Interest; Roche Holdings. M.
Forsyth: None. S. Gruschkus: None.
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Detection of Homologous Recombination Repair Defects in
NSCLC
H. Willers1, L. Kachnic2, M. Birkelbach3, N. Ferraiolo1, L. Gheorghiu1, B.
Daly2, M. Ebright2, C. O’Hara2, J. Dahm-Daphi3, J. Settleman1, 1Massachu-
setts General Hospital, Boston, MA, 2Boston Medical Center, Boston, MA,
3University of Hamburg, Hamburg, Germany
Purpose/Objective(s): In patients with advanced NSCLC treated with a
platinum doublet, tumor response rates are only in the range of 20–30%.
There is a paucity of biomarkers to predict which tumors are likely to
respond. Homologous recombination repair (HRR) is a major pathway for
the repair of DNA double-strand breaks (DSB) and required for cellular
resistance to platinum drugs. However, whether HRR defects exist in
NSCLC has not been established.
Results: We assessed the ability of 12 NSCLC cell lines to form subnuclear
foci of RAD51, a central HRR effector protein. Strikingly, 3 cell lines (25%)
were impaired in their ability to mount a RAD51 foci response to cisplatin.
We used staining for gamma-H2AX to show that DSB arise in S-phase in
response to cisplatin, as replication forks collapse at drug-induced interstrand
crosslinks. RAD51-deficient cells exhibited increased levels of unrepaired
DSB after 24 hours compared to repair-proficient cells. The HRR-defective
cell lines displayed at least 10-fold decreased survival after cisplatin treat-
ment in a colony formation assay. In 2 cell lines, the HRR defect could be
linked to known mutations in apical DNA damage response kinases. A third
cell line had reduced FANCL expression. However, other cell lines that
showed decreased expression of DNA repair genes by microarray were not
cisplatin-sensitive, suggesting that gene expression levels alone are insuffi-
cient to predict functionally relevant repair defects. We noted that chemo-
sensitivity was correlated with an impaired ability to induce RAD51 foci
following drug treatment but not with the baseline number of foci in
untreated cells. Thus, assaying RAD51 foci on archived tumor samples (from
pre-treatment biopsies) was not expected to be informative. We, therefore,
adapted an ex-vivo biomarker assay previously tested in breast cancer
(Willers et al. 2009, Mol Cancer Res 7, 1304). Viable tumor tissues from
patients with untreated NSCLC were exposed to cisplatin in the laboratory
and incubated for various time intervals before snap freezing. Serial cryo-
sections were analyzed for repair protein foci. We determined that tumor
explants are viable for at least 24 hours after removal from the patient.
Cisplatin-treated explants demonstrated induced gamma-H2AX and RAD51
foci compared to mock-treated samples. Interestingly, out of 12 tumors
analyzed to date, 3 (25%) showed an impaired ability to form RAD51 foci in
response to cisplatin, which mirrors our cell line results.
Conclusions: Using mechanism-based repair foci assays we show that
25% of NSCLC harbor a HRR defect that sensitizes the affected tumors to
cisplatin. Repair foci assays may represent a powerful tool for prospective
determination of chemosensitivity, but will require adapting ex-vivo tech-
niques to induce DNA damage. Supported in part by the Department of
Defense.
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Frequent High-level Amplification of Fgfr1 Associates With
Therapeutically Tractable Fgfr1 Dependency in Squamous-cell
Lung Cancer: A First Result of The Clinical Lung Cancer
Genome Project Initiative
R. Thomas, Max Planck Institute for Neurological Research, Cologne,
Germany
EGFR mutations and EML4-ALK fusions are associated with response to
EGFR and ALK inhibition in lung adenocarcinoma. By contrast, genetic
alterations exposing an immediate therapeutic vulnerability have so far been
lacking in squamous-cell lung cancer. As part of an international effort to
characterize clinically relevant cancer genome alterations across more than
1,000 clinically annotated lung cancer specimens (The Clinical Lung Cancer
Genome Project), we have performed a systematic search for such “drug-
gable” alterations. We employed high-resolution gene-copy number analyses
to a set of 232 lung cancer specimens and identified frequent (9.7% of cases)
and focal FGFR1 amplification in squamous-cell lung cancer (n155,
p0.0001) but not in other lung cancer subtypes and confirmed its presence
in an independent cohort of squamous-cell lung cancer employing FISH. We
performed cell-based screening employing a potent FGFR1 inhibitor
(PD173074) across a large (n82) panel of lung cancer cell lines. We found
that PD173074-mediated growth inhibition and apoptosis was specifically
related to the presence of FGFR1-amplification in lung cancer cells
(p0.001). Knockdown of FGFR1 strongly reduced the viability of
PD173074-sensitive and FGFR1-amplified lung cancer cells. Furthermore,
ectopic expression of a resistance allele of FGFR1 (FGFR1V561M) rescued
FGFR1-amplified cells from PD173074-mediated cytotoxicity. These results
formally validate the dependency on FGFR1 in FGFR1-amplified cell lines.
Finally small-molecule FGFR1 inhibition induced significant tumor shrink-
age in vivo in xenograft models of FGFR1-amplified lung cancer. In
summary, focal FGFR1 amplification represents the first therapeutically
tractable oncogene dependency in squamous-cell lung cancer. Thus, FGFR
inhibitors should be evaluated in this cohort of patient.
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Association of EGFR Activating Mutations With Low ERCC1
Gene Expression in Non-small Cell Lung Cancer (NSCLC):
Assessment of 1,207 Patients
D. Gandara1, P. Grimminger2, P. C. Mack1, P. N. Lara1, T. Li1, P. V.
Danenberg3, K. Danenberg4, 1Univ Of California Davis Cancer Ctr, Sacra-
mento, CA, 2University of Cologne, Cologne, Germany, 3Univ of Southern
California, Los Angeles, CA, 4Response Genetics, Inc., Los Angeles, CA
Purpose/Objective(s): NSCLC patients with activating mutations in EGFR
show improved efficacy from EGFR tyrosine kinase inhibitors. Some clinical
studies also suggest enhanced efficacy of platinum-based chemotherapy or
radiotherapy in patients with EGFR mutant cancers. We investigated the
relationship of EGFR mutation status and DNA repair capacity (as exem-
plified by ERCC1 gene expression) as a potential explanation for this
observation.
Materials/Methods: Microdissected FFPE tumors from 1,207 NSCLC pa-
tients were analyzed by RT-PCR for ERCC1 mRNA expression levels and
EGFR mutation status by an allele-specific PCR assay.
Results: Subtype was adenocarcinoma (AC) in 712 patients, squamous
(SCCA) in 175 and not otherwise specified (NOS) or other in 320. Median
ERCC1 expression was 1.82 (range 0.22–27.31) and was histology-related:
AC: median1.68 (0.22–11.33); SCCA: median2.42 (0.51–14.28)
(p0.001). Using a previously defined reference level of 1.7, ERCC1 was
low in 556/1207 (46.1%). EGFR activating mutations were detected in
183/1,207 (15.2%) and consisted of E19del (n106), L858R (n56) or other
(n21). EGFR mutations were highly associated with ERCC1 expression
(p0.001). Median ERCC1 was 1.47 (0.32–8.24) in EGFR mutant cancers
versus 1.88 (0.22–27.31) in EGFR WT. This association was retained when
adjusting for AC histology (p0.001). There was a trend for lowest ERCC1
levels in patients with E19del mutations: median 1.35 (0.32–4.43) versus all
other mutations: 1.69 (0.36–8.24) or L858R: 1.56 (0.36–8.24), p0.124.
Conclusion: NSCLC harboring EGFR activating mutations are more likely
to express low ERCC1 mRNA levels. Whether these findings translate into
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enhanced clinical efficacy of EGFR-mutant cancers to platinum-based che-
motherapy remains to be determined, and will be addressed by a prospective
trial (CASTLE).
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Should All Non-small Cell Lung Cancers be Tested for EGFR
Activating Mutations?
M. Fidler1, L. Buckingham1, S. Basu1, K. A. Kaiser-Walters1, M. Pool1, M.
Batus1, J. Coon1, T. Hensing2, P. Bonomi1, 1Rush University Medical
Center, Chicago, IL, 2Evanston Hospital, Evanston, IL
Purpose/Objective(s): NSCLC patients with an EGFR activating mutation
have an improved progression free survival compared with front line che-
motherapy (Mok et al NEJM 2009). Recent data characterizing clinical
characteristics of EGFR mutation carrying patients in a large Spanish
population showed that the majority of positive cases had adenocarcinoma
histology (80.9%) and 66.6% had a history of never-smoking. There are little
data relating multiple clinical characteristics and the frequency of EGFR
gene mutations in American-European patients. This study correlates clinical
characteristics with EGFR mutated NSCLC patients from Evanston Hospital
and Rush University Medical Center.
Materials/Methods: This study included patients treated on the Gefitinib
Expanded Access trial or with erlotinib in a retrospective study being
conducted at Rush University Medical Center and Evanston Hospital. Tumor
cells were microdissected from thin sections of available fixed tissue. Exon
19 gene mutations were detected by PCR-single strand confirmation poly-
morphism analysis and the exon 21 L858R mutation was detected by
sequence-specific PCR. The presence of the EGFR gene mutation was
correlated with clinical characteristics of gender, smoking history and his-
tology.
Results: 169 patients had EGFR gene mutation analysis. 98(58%) patients
were women, 116 (69%) patients had adenocarcinoma, and 31 (18%) patients
were never smokers. Most tumors in never smokers had adenocarcinoma
(87%). EGFR activating mutations were present in 32 (19%) patients. 26.9%
of adenocarcinoma patients vs. 3.9% of non-adenocarcinoma patients had the
EGFR gene mutation (p.001). 48.4% of never smokers had an activating
mutation vs. 13.1% of patients with a smoking history (p.001). Among
adenocarcinoma patients with a history of smoking, 17.4% of patients had
the EGFR gene mutation present. Among non-adenocarcinoma patients with
a history of smoking, only 4.2% of patients had the EGFR gene mutation
present. In a multivariate logistic regression analysis, adenocarcinoma and
never smoking were associated with having an EGFR gene mutation (p 
0.015, p0.001, respectively) while gender was not significantly associated
(p0.32).
Conclusion: Controversy exists in who should be offered front line EGFR
gene mutation testing in NSCLC patients. These results suggest not using
gender to exclude testing for the EGFR gene mutation but questions the
cost-effectiveness of testing non-adenocarcinoma patients with a history of
smoking. In our study, the group of current or former smokers with adeno-
carcinoma had a relatively low percentage of mutation positive patients and
further validation, especially in this subset of patients, is warranted.
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Genentech. F. Consulting/Advisory Board; Genentech. L. Buckingham:
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The Value of Primary Tumor Maximum Standardized Uptake
Value (SUV) From a Staging Positron Emission Tomography
(PET) Scan as a Predictor of Clinical and Pathologic Outcomes
in Patients Undergoing Trimodality Therapy for Locally Ad-
vanced Lung Cancer
L. J. Sheplan Olsen, C. Reddy, D. Adelstein, N. Pennell, M. Shapiro, D.
Mason, S. Murthy, T. Rice, G. Hunter, G. Videtic, et al., Cleveland Clinic,
Cleveland, OH
Purpose/Objective(s): PET SUVs may provide prognostic information in
managing non-small cell lung cancer (NSCLC) patients (pts), as they may
predict for response to therapy. Since potentially resectable stage III pts have
been treated in our institution using a standardized regimen, we looked at
absolute values of primary tumor maximum SUV (tSUV) and maximal nodal
SUV (nSUV) from the staging PET and compared them to pathologic
outcomes to see if they could act as predictors of response following
neoadjuvant chemoradiation (nCRT).
Materials/Methods: From an IRB-approved data registry, we retrospec-
tively reviewed all staged, potentially resectable, mediastinoscopy-con-
firmed stage III NSCLC pts for the interval 1/1/1999 to 12/31/2008.
Treatment consisted of nCRT (30 Gy at 1.5 Gy twice daily over two
weeks with concurrent platinum/taxane week 1) followed by surgical
resection and, 4-6 weeks later, an identical CRT course adjuvantly. A
cohort of pts was also registered to our institutional phase II trial looking
at the addition of erlotinib. Relevant pt, tumor, treatment and pathologic
variables, including staging SUVs, were required for inclusion.
Results: Ninety pts (58 male, 32 female) met the criteria for analysis.
Median follow-up was 20.15 mo. Median age was 62.5 yrs (range:
33-78). Median KPS was 90. T stage was 1, 2, 3 and 4 in 33.3%, 46.7%,
4.4%, and 15.6% of pts respectively. N stage was 0, 1, and 2 in 17.8%,
47.8%, and 16.7% of pts respectively. Forty-nine percent of pts received
erlotinib. Tumor (T) downstaging (DS) was seen in 48.9% and upstaging
(US) in 7.8% of pts. Nodal (N) DS, from staging mediastinoscopy to
surgical resection, was seen in 43.3% and US in 3.3% of pts. Forty-eight
percent, 18%, and 60% of pts developed metastasis, local recurrence and
death, respectively. Median survival was 27.4 mo and median metastasis
free survival was 37.0 mo. Mean tSUV was 10.84  6.69 and 8.12  3.79
(p0.037) for the T DS and T not-DS groups, respectively. An SUV
cutoff of 9 as predictor of T DS showed an odds ratio of 2.51 with a trend
to significance (p0.0507). Univariate logistic regression for tSUV effect
on T DS showed an OR of 1.105 (p0.046). Mean tSUV was 9.10  6.08
and 9.90  5.38 (p0.557) for the N DS and N not-DS groups,
respectively. Cox proportional hazards regression for tSUV correlation to
recurrence, metastasis and overall survival were not significant (p0.75,
0.66, and 0.79, respectively).
Conclusions: Staging tSUV is predictive of pathologic T DS following
nCRT, but does not correlate to N DS. An SUV cutoff of 9 showed a trend
to significance as a predictor of T DS. No correlation was seen between
tSUV and recurrence, metastasis or overall survival rates.
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Reduced Disease-free Survival Associated With Anaplastic
Lymphoma Kinase Translocation (ALK) in Lung Adenocar-
cinoma Patients With No Cigarette Smoking History
P. Yang1, A. Oliveira1, J. Wampfler1, J. Boland1, S. Stoddard1, M. Erickson-
Johnson1, H. Tang1, K. Kulig2, E. S. Yi1, 1Mayo Clinic, Rochester, MN,
2Pfizer Oncology, New York, NY
Purpose/Objective(s): The natural history of ALK and NSCLC clinical
outcome needs to be defined. We designed a nested case-control study using
the ongoing Mayo Clinic Lung Cancer Cohort to evaluate clinical outcomes
of never-smoking lung adenocarcinoma patients with respect to ALK trans-
location status and report preliminary results.
Materials/Methods: We employed IHC (Dako clone ALK1 with AD-
VANCE detection chemistry, Carpinteria, CA) and FISH with dual color
break-apart probe (Vysis, Des Plaines, IL) on formalin-fixed paraffin-em-
bedded tissue to test for ALK. In this study, we have analyzed disease-free
survival (DFS), which was defined as free of progression and/or recurrence
and was systematically assessed in the Mayo Lung Cancer Cohort study
through medical record abstraction, supplemented with direct outreach to
patients or family members and by requesting necessary records from
external health care providers. We considered ALK if FISH or IHC
scored 23, ALK- if FISH- or IHC scored 0. To control for known
prognostic indicators of lung cancer survival, matching criteria were used to
create comparable sets of ALK vs ALK- cases. Matching variables were
age, sex, and stage. Set 1 includes 10 FISH and 10 FISH- cases with age
10 years and 2 stages (III, IIIIV); Set 2 includes 7 FISH and 7 FISH-
with age 5 years and 3 stages (III, III, IV). A multivariable Cox
proportional hazard model was also applied to all ALK vs ALK- cases
adjusting for age, sex, and stage, by FISH and IHC separately.
Results: To date, a total of 159 cases were tested by IHC, of which, 100 were
confirmed by FISH, 10 ALK and 90 ALK-. IHC scored 0, 1, 2, and 3,
respectively for 95, 46, 7, and 11 cases. We found a complete concordance
between FISH- and IHC-0 cases, and 10 of 11 (91%) IHC-2 and IHC-3 were
FISH. For Set 1, median DFS is 30.3 months for ALK vs. 57.4 months
for ALK- cases (p  0.195). For Set 2, median DFS is 26.5 months for
ALK vs. 63.4 months for ALK- cases (p  0.193). The multivariable Cox
model revealed a hazard ratio of 1.93 (p0.09) for DFS for ALK vs ALK-
cases by FISH test, and a hazard ratio of 1.87 p0.06) by IHC test.
Conclusion: Our preliminary analysis of 159 never-smoking adenocarci-
noma cases suggests a trend of worse outcome, as measured by DFS, in
patients with ALK tumors. Our continued screening for ALK status in this
cohort will allow more robust analyses, including evaluation of treatment-
specific outcomes in matched ALK vs. ALK- patients.
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FEV1 as Prognostic Marker in Stage III Non-small Cell Lung
Cancer (NSCLC) Patients Treated With Chemoradiation:
Pooled Analysis of Two Multicenter Phase II Trials
P. R. Germonpre1,2, A. Janssens1,2, V. Nowe´1,2, C. De Pooter2,3, C. Goor1,4,
1Antwerp University Hospital, Edegem, Belgium, 2Thoracic Oncology Group
Antwerp - University of Antwerp, Antwerp, Belgium, 3St. Augustinus, Wilrijk,
Belgium, 4ZNA Middelheim, Antwerp, Belgium
Purpose/Objective(s): Lung cancer mortality has been shown to be signif-
icantly associated, both in smokers and non-smokers, with emphysema and
chronic bronchitis. An exploratory analysis of the HOG 01-24 trial suggests
that FEV1 (forced expiratory volume in 1 sec) 2L was associated with
improved OS in stage III NSCLC patients (pts) treated with chemoradiation.
In this analysis we evaluated the prognostic value of FEV1 (expressed as %
of predicted value).
Materials/Methods: We used individual data from 71 pts enrolled in two
multicenter phase II trials to perform a univariate analysis of prognostic
factors using the log-rank test. Pts with unresectable stage III NSCLC and
performance status (PS) 0-2, weight loss 10%, FEV1 1.2L or 45%,
diffusion capacity (DLCO) 50% and adequate organ function were en-
rolled in the Cher@Nos (from 02/2003 to 11/2005) and the Paccora trials
(from 01/2006 to 12/2008). Treatment consisted of 3 cycles of carboplatin 
gemcitabine followed by thoracic radiotherapy with concurrent weekly
low-dose cisplatin in the Cher@Nos trial, and of 3 cycles of cisplatin 
pemetrexed (either as induction or consolidation) and thoracic radiotherapy
with concurrent 3-weekly pemetrexed in the Paccora trial. In both trials the
radiotherapy was administered as 2 Gy/fraction, 5 fractions/week for a total
dose of 60 Gy.
Results: Pts with an FEV1 70% predicted had a significantly better
progression-free survival (PFS) and overall survival (OS) compared to pts
with an FEV1 70% predicted: HR 0.289 (0.132-0.633; Chi
2 P .002) for
PFS and HR 0.319 (0.161 - 0.635; P .002) for OS. Gender, PS, stage (IIIA
vs. IIIB), histology (squamous vs. non-squamous) and trial (Paccora vs.
Cher@Nos) were not associated with a significant difference in PFS or OS.
Conclusion: Our data confirm the prognostic value of FEV1 (70% vs.
70% predicted) in pts with unresectable stage III NSCLC treated with
chemoradiation. Furthermore these results indicate that FEV1 is a potentially
important but often ignored confounder when interpreting results from
different chemoradiotherapy trials or when designing new trials comparing
different chemoradiotherapy regimens.
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Stereotactic Body Radiotherapy (SBRT) in Patients Aged 75 and
Older With Stage I Non-small Cell Lung Cancer (NSCLC):
Retrospective Results From a Multi-Center Consortium
M. A. Samuels1, S. Kandula2, J. A. Bogart3, J. Salama4, P. Aridgides3, A.
Gajra3, R. C. Lilenbaum1, 1Mount Sinai Community Clinical Oncology
Program, Miami Beach, FL, 2University of Miami School of Medicine,
Miami, FL, 3SUNY Upstate Medical University, Syracuse, NY, 4University of
Chicago School of Medicine, Chicago, IL
Purpose/Objective(s): Patients aged 75 and older comprise an increasing
proportion of patients with early lung cancer, and represent an even larger
proportion of patients unsuitable for definitive surgery due to medical
comorbidity or patient refusal. SBRT has recently become an accepted
treatment option for patients with contraindications to surgery. We report a
retrospective analysis of the clinical outcomes of a series of elderly patients
treated with SBRT in the setting of a multi-institutional clinical research
consortium.
Materials/Methods: Three institutions pooled retrospective data on all
patients aged 75 or over who received SBRT for stage I NSCLC. 47 patients
were available for analysis, with ages ranging from 75 to 92 years (median
81). Treatment was delivered during the 2007-2009 time period with a
median follow-up of 8.1 months. All patients had staging with PET-CT. 87%
of patients had biopsy-proven disease. 55% had poor pulmonary function,
19% had other medical comorbidities, 21% refused surgery and for 5% the
reason was unknown. 51% had T1a tumors, 32% had T1b and 17% had T2a
tumors. Total doses were 35-60 Gy in 3-9 fractions. All patients were treated
using a linear accelerator, with 96% receiving 3D conformal RT and 4%
undergoing IMRT. Patients were followed for toxicity and tumor control.
Results: At the time of analysis, the local failure rate was 2% (1/47). The
regional failure rate was 9% (4/47). The distant failure rate was 6% (3/47).
Abstracts Journal of Thoracic Oncology • Volume 5, Number 12, Supplement 7, December 2010
Copyright © 2010 by the International Association for the Study of Lung CancerS518
